Please go to the PowerPak homepage
and select a course.
This program is jointly provided by The University of Tennessee College of Pharmacy, and Catalyst Medical Education, LLC.
This activity is supported by an educational grant from Epizyme, Inc.
May 27, 2022
May 27, 2023
Epithelioid sarcoma (ES) is a rare soft tissue sarcoma that accounts for <1% of all adult cancers and for approximately 15% of pediatric malignancies. It has high overall rates of recurrence and metastasis and is often misdiagnosed.
This activity will review the diagnosis and management of ES and examine the role of epigenetics within current therapeutic recommendations, given the availability of epigenetic-targeted therapies such as EZH2 inhibitors. Case vignettes will be presented to highlight the pharmacist’s role in the management of ES within the oncology care team, including the oversight of therapeutic plans and the safety evaluation of prescribed medicines for patients with ES.
This initiative is intended for oncology pharmacists, as well as hospital, managed care, and specialty pharmacists
Upon completion of this activity, participants should be better able to:
- Summarize the criteria for the differential diagnosis for ES to inform treatment decision-making
- Describe the mechanisms of action of EZH2 inhibitors to address pathology of ES
- Evaluate the most recent efficacy, safety, and PK data on EZH2 inhibitor therapy for ES
- Integrate pharmacist-driven strategies into ES management to optimize the use of new therapies
Mrinal Gounder, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Theresa Stehmer Brown, PharmD, BCOP, CPP
Clinical Oncology Pharmacist
Duke University Health System
Mrinal Gounder, MD, has disclosed the following relevant financial relationships: Speaker: Medscape, More Health, Physicians Education Resource, touchIME; Consultant: Wolters Kluwer, patents with MSKCC (GODDESS PRO), Athenex, Ayala, Bayer, Boehringer Ingelheim, Daiichi, Epizyme, Karyopharm, Rain, Springworks, Tracon, TYME, Guidepoint, GLG, Third Bridge, Flatiron Health
Theresa Stehmer. Brown, Pharm.D., BCOP, CPP has disclosed the following relevant financial relationships: Employment: Spouse is an employee of Aerie Pharmaceuticals
All of the relevant financial relationships listed for these individuals have been mitigated
Type of Activity: Application-based
Fee Information: There is no fee for this educational activity
CONTINUING EDUCATION INFORMATION
University of Tennessee College of Pharmacy is accredited by the
Accreditation Council for Pharmacy Education (ACPE) as a provider of
continuing pharmacy education. Successful completion of this
application-based activity will provide a statement for 1.0 home study
contact hours credit (0.10 CEUs). Successfully completing the activity
and receiving credit includes: 1) viewing the educational activity in
its entirety; 2) successfully completing the post-test; 3) completing
the educational activity evaluation form. UAN: 0064-9999-22-014-H01-P. It
is recommended that you check your NABP CPE Monitor e-profile database
30 days after the completion of any CE activity to ensure that your
credits are posted. The ACPE accreditation expiration date is May 27, 2023.
- NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service.
- To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.
- First time participants will be required to setup a profile. All participants should complete an evaluation and submit a claim for CPE credit
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at email@example.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.